EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

This study tests EBNK-001, an engineered immune cell therapy using natural killer (NK) cells combined with a low dose of IL-15 (a protein that supports immune cell activity), with or without the immunotherapy drug pembrolizumab, in adults with advanced solid tumor cancers that have stopped responding to standard treatments. **You may be eligible if...** - You are 18 or older - You have a confirmed advanced or metastatic solid tumor that has relapsed or is no longer responding to standard therapy, or there is no standard treatment available - Your cancer can be measured on imaging scans - Your overall health is good (ECOG 0-2) - Your blood counts and major organ function are within acceptable limits **You may NOT be eligible if...** - You have an active uncontrolled infection - You have active autoimmune disease requiring systemic immune-suppressing medications - You are known HIV positive or have active hepatitis B or C with detectable viral levels - You are pregnant or breastfeeding - You have received another investigational drug within 28 days before treatment start - You received a live vaccine within 6 weeks before starting lymphodepletion (a preparatory step for the cell therapy) Talk to your doctor to see if this trial is right for you.